ANAB AnaptysBio Inc. Total Debt to Capital

The stability of AnaptysBio, Inc. (ANAB) is confirmed by its resilience to geopolitical supply risks, as evidenced by the ratio of total liabilities to equity. The operational base relies on the drive for efficiency within the crowded immunotherapy sector, while the patent moat and FDA requirements block new entrants. The value of 26.79 serves as the final mark for this leverage metric.

In the biotechnology sector, the balance of borrowed funds determines the stability of new drug development. The ratio compares total liabilities to net assets, measuring the degree of financial leverage. Analyzing total debt relative to equity reveals the company's deleveraging pace. This is critical for AnaptysBio, Inc. (ANAB), as royalties from Jemperli allow the company to fund its immune pipeline without excessive loans. Low indebtedness minimizes risks during the scaling of Phase 2.